Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial.

Although the borderline significant interactions of baseline BMI with change in leptin and of insulin with change in hsCRP may have been due to chance (multiple interactions were tested for multiple variables) they warrant evaluation in future studies; it is important to note that these potential interactions were quantitative, not qualitative with metformin (vs placebo) benefits being consistently observed.

also in 11,409 other papers